INTRODUCTION

C
ajanus cajan (L.) Millsp. (Fabaceae), commonly known as "Pigeon pea" (English), "Fio-fi o" (Igbo -Nigeria), "Guandu" (Brazil), and caja or "Puspo-poroto" (Peru), is an erect woody and annual or short-lived perennial shrub or small tree that is widespread and cultivated throughout the tropics and subtropics. Th e seeds (pigeon peas) are popular food in developing countries. In Africa, Asia and South America diff erent parts of the plant are used in the management of disorders such as ulcer, diarrhea, pain, diabetes, cough and sores. Th e plant, often grown as a shade crop is commonly used all over the world for the treatment of diabetes, dysentery, hepatitis, measles, as a febrifuge, and to stabilize menstrual period (1) (2) (3) (4) . In traditional Chinese medicine, the leaves of pigeon pea have been widely used to relieve pain and kill worms (5) , for the treatment of wounds, bedsores and malaria, as well as diet-induced hypercholesterolemia (6) (7) (8) . Protective eff ects of the leaf extracts against hypoxic-ischemic brain damage and alcoholinduced liver damage have also been reported (9, 10) . Th e antioxidant activity of the extract of the leaves (11) and the hypoglycemic activity of the seeds have been reported (3) .
Th e isolation of antiplasmodial compoundsbetulinic acid (roots), longistylin A and C (leaves) from the plant has been reported (12) .
In line with the ethnomedicinal use of the plant in the treatment of diabetes in Nigeria and other parts of the world, we evaluated the antihyperglycemic potentials of C. cajan leaf extract in diabetic rats.
MATERIALS AND METHODS
Animals
Adult Swiss albino rats (150 -250 g) of either sex bred in the Laboratory Animal facility of the Department of Pharmacology and Toxicology, University of Nigeria, Nsukka were used for the study. Th e animals were maintained on standard pellets and water, and allowed 2 weeks for acclimatization before use. All animal experiments were in compliance with the National Institute 2% w/w), which was subsequently subjected to phytochemical analysis using standard procedures (13, 14) .
Acute toxicity tests
Th e acute toxicity and lethality (LD 50 ) of the extract was determined in rats using the method described by Lorke (15) . Briefl y, nine rats randomly divided into three groups (n=3) received oral administrations of 10, 100, and 1000 mg/kg of the extract respectively and were observed for 24 h for death. Since no death was recorded, 1,600, 2,900 and 5,000 mg/kg of the extract were administered to a fresh batch of animals and the number of deaths in 24 h recorded.
Effect of extract on fasting blood glucose in alloxan-induced diabetic rats
Diabetes was induced by intraperitoneal injection of alloxan monohydrate (100mg/kg; i.p.) (16, 17) to normal healthy Swiss albino rats fasted for 12 h. Th e animals were housed in cages for 48 h with access to food and water. Subsequently, the 12 hour fasting blood glucose level (FBGL) was determined and rats with blood glucose level (BGL) > 250 mg/dl were considered diabetic and used for the study. Th e diabetic rats were randomly placed into groups (n=6) to receive oral administrations of CCM (400 or 600 mg/kg) suspended in tween 80 (10% v/v). Th e standard group received glibenclamide (0.5 mg/kg) while the control group received the vehicle (Tween 80, 5 ml/kg). Blood was withdrawn from each animal by tail snipping and blood glucose levels were determined for each animal in each group at fi xed intervals 0, ½, 1, 2, 4, 6, and 8 h, using One touch® glucometer kit (Lifescan, Johnson and Johnson Company, Milipitas, CA).
Oral glucose tolerance test in normoglycemic rats
Rats fasted for 16 h but with free access to water were randomly divided into four groups (n = 6) and received oral administrations of CCM (400 or 600 mg/kg) suspended in Tween 80 (10% v/v). Th e standard group received glibenclamide (0.5 mg/kg) while the control group received the vehicle (Tween 80, 5 ml/kg). Ninety minutes later, the rats were orally fed with glucose (4 g/kg) (18) 
Statistical analysis
Data obtained was analyzed using One-Way analysis of variance (ANOVA) and further subjected to LSD post hoc test for multiple comparisons. Th e results were presented as Mean ± SEM. Diff erences between means of treatment and control groups were accepted signifi cant at P<0.05.
RESULTS
Phytochemical constituents
Th e phytoconstituents detected in the leaves include saponins, tannins, terpenoids and resins (Table 1) .
Acute toxicity and lethality (LD50) test
Th e LD50 was estimated to be greater than 5000 mg/kg. 
Effect of CCM on FBGL in alloxan diabetic rats
Th e two doses of the extract caused a signifi cant, dose-related and progressive reduction in fasting blood glucose level up to 6 h, compared to control. Also the hypoglycemic eff ect elicited by CCM (600 mg/kg) was greater than that of glibenclamide up to the 4th hour ( Table 2) .
Effect of CCM on oral glucose tolerance
Within 30 min of administration of glucose load, there was a progressive increase in the postprandial blood glucose level (BGL) of all the rats which peaked at 60 min. At 60 min, the CCM treated groups (400 and 600 mg/kg) had 78.93% and 123.32% increase in BGL compared to control (180.72%). Hence treatment with CCM suppressed the rise in BGL at 60 min by 101.79% (400 mg/kg) and 57.40% (600 mg/kg). Th e CCM evoked a progressive, signifi cant and non-dose related decrease in BGL up to 180 min, at which the BGL were close to or below basal levels (Table 3) .
DISCUSSION
Besides drugs classically used for the treatment of diabetes mellitus (DM), (insulin, sulphonylureas, biguanides thiazolidinediones, α-glucosidase inhibitors and others), several species of plants are used in various parts of the world to manage diabetes. Also the hypoglycemic and antidiabetic activities of many plants are documented in scientifi c literature (18) (19) (20) (21) . Evaluation of the hypoglycemic activity of CCM in alloxan-induced diabetic and normal hyperglycemic rats showed that the extract reduced blood glucose levels and also suppressed postprandial hyperglycemia in rats.
Oral administration of the extract to diabetic rats elicited signifi cant and dose related hypoglycemic eff ect, suggesting benefi cial eff ect in DM. Alloxan monohydrate induces diabetes by destruction of the β-cells of Islets of Langerhan's with consequent impairment of insulin secretion leading to hyperglycemia (22-24). Hence, the extract may act through mechanism(s) that enhance/boost insulin secretion. In addition, eff ective and sustained reduction in blood glucose levels of treated diabetic rats by the extract indicates that it may be useful in overt cases of DM.
Th e extract also suppressed the rise in blood glucose level after a heavy glucose meal with maximum suppression at 60 min, the time of peak postprandial hyperglycemia; this indicates an ability to suppress and control postprandial hyperglycemia. Chronic hyperglycemia, a risk factor for the development of life threatening and other complications of DM, is constantly fuelled by postprandial elevation of blood glucose. Hence, control of postprandial hyperglycemia is of great importance due to its strong association with the risk of micro and macro-vascular complications and death (25, 26) . Interestingly, in addition to hypoglycemic eff ect, the extract may also suppress postprandial rise in blood glucose level both of which are indices of eff ective glycemic control.
Th e glucose lowering eff ect observed in the extract may be attributable to the presence of saponins, terpenoids, resins and tannins. Tannins isolated from some antidiabetic medicinal plants have been found to stimulate secretion or possess an insulin like-eff ect (27) . In addition, terpenoids like clerodane-type diterpenes from the stem bark of Croton cajucara have been shown to possess hypoglycemic properties (28, 29) . Th e LD 50 estimated to be greater than 5000 mg/kg, indicates that the extract is relatively safe.
In conclusion, the results of the study demonstrate the potentials of the leaves of C. cajan as anti-diabetic therapy, which may be attributable to hypoglycemic activity and an improvement of post prandial hyperglycemia in diabetes mellitus.
